Ashvini Keshavan
@AshviniKeshavan
Followers
229
Following
324
Media
9
Statuses
128
Neurologist, Early Career Researcher in Dementia, Ageing & Fluid Biomarkers @UCL, Odissi dancer. Views expressed are my own.
Joined January 2021
On Thierrault et al.’s excellent meta-analysis of the diagnostic accuracy of plasma p-tau in cognitively impaired and cognitively unimpaired populations
thelancet.com
Plasma p-tau217 is a highly sensitive and specific biomarker for Alzheimer's disease pathology, despite the high risk of bias of many studies. Prospective clinical implementation studies in real-wo...
0
0
3
Plasma p-tau, particularly p-tau217, has the potential to revolutionise Alzheimer’s diagnosis; now we must prove it improves patient care and accelerates treatment access when used with a thorough clinical assessment - our comment in Lancet Neurology today
thelancet.com
More than 82 million people could be living with dementia by 2030,1 the majority in low-income and middle-income countries where access to specialist care and diagnostic tests is highly variable....
1
6
23
Great working on this with Jo Rodda (@UniKent), @Lindseykuchen Alicia Algeciras-Schimnich @mayoclinic and many others on an international team! 5/5.
0
0
0
What would increase clinician confidence in using AD BBM? .· More data on test performance in own patient population.· Educational resources & tools to aid result interpretation.· Better resources to counsel patients on implications of results for treatment decisions 4/5.
1
0
0
Clinicians almost evenly split on AD BBM being ready for use in their current clinical practice.Most agreed AD BBM are useful in aiding diagnosis in MCI or dementia; most disagreed with use in asymptomatic people - in line with current appropriate use recommendations 3/5
1
0
0
212 clinicians, most working in primary or secondary care, most in neurology, psychiatry or gerontology 2/5
1
0
0
🚨 New paper alert! Out in @alzdemjournals *open access* today! Global clinician perspectives on Alzheimer blood biomarker implementation - a publication by the Real World Translation Work Group @FluidMarkersPIA @ISTAART Read on for key messages 1/5.
alz-journals.onlinelibrary.wiley.com
INTRODUCTION Clinicians’ views on the clinical readiness of Alzheimer's disease (AD) blood biomarkers (BBMs) are not well understood. METHODS The Alzheimer's Association International Society to A...
2
2
4
It was great to be able to update on plans for the ADAPT study on @BBCRadio4 and thanks @SelinaWray for hosting in your lab and sharing the amazing work you are doing with organoids to elucidate disease mechanisms and allow for screening of therapeutic targets!.
Great to see @AshviniKeshavan on @BBCRadio4's Inside Health show today, discussing what's next for dementia research following the NICE decisions on lecanemab and donanemab. Listen here 👇
0
0
8
Great experience to facilitate and author this paper with @NicholasAshton @wagnersbrum @jmschott Henrik Zetterberg - unprecedented level of industry and academic collaboration showing p-tau217 has highest fold change in symptomatic AD over non-AD participants from @drcionucl.
🚨 Available as a preprint – The @alzassociation #pTau round robin study 🚨. 📣 33 different ways to measure #blood #pTau.📣 Mass Spec, semi & fully-auto immunoassays.📣 #pTau217 consistently best .📣 Corr. between assays = optimism for standardisation .
0
6
20
RT @NicholasAshton: The collection of #blood #biomarkers studies using NULISA as presented at day two of #AAIC2024 is now available as a….
0
11
0
RT @smead2: Post-Doctoral Research Fellow to work at the MRC Prion Unit at UCL on multiplexed seed amplification assays in mixed dementia,….
ucl.ac.uk
UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).
0
10
0
Looking forward to this opportunity to discuss blood tests for Alzheimer’s, answer questions from the public, and speak about the ADAPT study - all welcome, register to join at 13:00 UK time today!.
What does the future of diagnosing dementia look like? Could blood tests revolutionise the process, making it quicker & easier?. Join our scientists Dr Maura Malpetti & Dr Ashvini Keshavan as they delve into these important questions & more. Sign up now!
0
3
11
Do apply to work with this great team on the innovative DIADEM study looking at both digital auditory and blood biomarkers in real world memory clinics, headed by @charl_marshall & Chris Hardy at UCL.
QMUL @preventiveneur1 seek a Research Assistant to evaluate the utility of digital auditory biomarkers to support the diagnosis of Alzheimer’s and stratification of patients with mild cognitive disorder in NHS memory clinics. Closing date: 10th June.
0
2
8
Thanks for the interview; privileged to lead the ADAPT study with @jmschott @ucl - buzzing from our first in person steering group meeting with protocol drafting, patient/public engagement, staff recruitment and collaboration with @imperialcollege @LSEnews @UniKent all underway!.
Dr @AshviniKeshavan @drcionucl will co-lead the Blood Biomarker Challenge, which aims to revolutionise dementia diagnosis. Read the interview ➡️ #DementiaActionWeek #DAW2024 #UCLDementia
0
5
12
RT @PareshMalhotra: Academic clinical lecturer post in #Neurology @ImperialBrains with a focus on #Dementia & opportunities to work with….
0
25
0
Thanks @AsianVoiceNews for the coverage of the role that the Blood Biomarker challenge grant award will play in bringing accurate dementia diagnosis to local communities in the UK, and for featuring the ADAPT study. @ARUKscientist @alzheimerssoc.
0
0
6
RT @thenewsdrum: Indian-origin neurologist @AshviniKeshavan's UK study to revolutionise dementia diagnosis . #Neurology #dementia #Alzheime….
newsdrum.in
An Indian-origin neurologist is part of a world-class research team in the UK that has been awarded a major grant this week to build on recent breakthroughs in...
0
1
0
RT @UCLHresearch: A world-class research team @uclh and @UCLIoN led by @jmschott & @AshviniKeshavan has been awarded £3.76m to carry out a….
0
12
0
Honoured to be co-leading the ADAPT study of plasma p-tau217 in the UK with @jmschott, bringing together expertise from @ucl in dementia research @drcionucl, nationally accredited lab @uclh, patient&public engagement @UniKent, cost-effectiveness @LSEnews.
Great to announce that teams @UCLIoN and @DementiasUK have both been awarded the Blood Biomarker Challenge. The @ucl team will test the diagnostic utility of ptau217 for Alzheimer’s in @NHS memory clinics. @alzheimerssoc @AlzResearchUK @NIHRresearch @BBCr4today @UKDRI
1
5
36